Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518139 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,060
- Enrollment target
- 1
- Study location
NCT02518139: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mylan.
NCT02518139 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Mylan. The registered enrollment target is 1,060 participants, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02518139, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,060 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
Primary Outcome
To assess the safety and tolerability of TD-4208 by assessing the frequency and severity of Treatment Emergent Adverse Events (TEAE)
Conditions Studied
Interventions
- DRUG Tiotropium
- DRUG TD-4208
Study Locations (1)
South Carolina
- Palmetto Medical Research Associates L.L.C - Easley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,060 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
What the finished NCT02518139 record still lists
NCT02518139 is an interventional study that assigns participants to a tested intervention. Its 1,060 participants enrollment target places it among the larger protocols in the corpus, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (70% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Tiotropium is the first listed.
NCT02518139 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT02518139 about?
NCT02518139 is a clinical study titled "A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
What is the current status of trial NCT02518139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,060 participants. The study started on 2015-09. Estimated completion is 2017-06.
What conditions does trial NCT02518139 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT02518139?
The interventions under investigation include: Tiotropium (DRUG), TD-4208 (DRUG).
Who is sponsoring clinical trial NCT02518139?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02518139 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02518139's enrollment target sits among peer trials
1,060 11th of 36 higher than 26 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia